Regnum Corp.

Regnum Corp.

RGMP - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$2.3K
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Regnum Corp.Regnum Corp.0-52%--1.2

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$2,295.00
Enterprise Value$1.11 Million
Earnings per Share$-0.03
Beta-0.91
Outstanding Shares22,950,000

Return

Return on Equity52.18%ROE
Return on Assets-142.11%
Return on Invested Capital48.85%

Valuation & Multiples

P/E Ratio0P/E Ratio
PEG0.01PEG
Price to Sales-Price to Sales
Price to Book Ratio-0.0Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-1.68
Enterprise Value to Net Income-2
Total Debt to Enterprise1.42
Debt to Equity-1.16Debt to Equity

Revenue Sources

No data

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Regnum Corp.

1 employees
CEO: Robert J. Stubblefield

Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody C—C chemokine receptor type 5 antagonist, that is designed to prevent human immunodefi...